The Chinese minimally invasive robot developer Ronovo Surgical announced it has raised $67 million to expand the commercial ...

Eli Lilly is inviting early-stage biotechs to make use of drug discovery models that the pharma is providing via an new AI ...

Novartis is paying $1.4 billion to get its hands on Tourmaline Bio and its former Pfizer cardiovascular drug that impressed ...

The infectious disease testmaker OraSure Technologies is coming under additional pressure from investors, according to ...

Pfizer veteran Suneet Varma has found his next role. Months after leaving the Big Pharma, Varma has taken the CEO position at the newly created inflammation and immunology startup Intent Biologics.

Capricor Therapeutics has publicly released its July response to the FDA's rejection of its Duchenne muscular dystrophy cell therapy deramiocel after the agency included deramiocel in a new batch of ...

Despite the stagnant biotech IPO market of the last six months, LB Pharmaceuticals has set out plans to reel in hundreds of ...

After previously delaying its decision date, the FDA has outright rejected Saol Therapeutics’ investigational treatment for ...

Servier is souping up its neurology pipeline with a clinical-stage candidate sourced from U.K. biotech Kaerus Bioscience for ...

Regeneron’s allergen-blocking antibodies have reduced the symptoms of cat and pollen allergies in a pair of phase 3 studies.

BioNTech’s chief medical officer, Özlem Türeci, M.D., described the findings as “very consistent” with the drug’s previous ...

Takeda and Alkermes both took data from their orexin receptor 2 (OX2R)-selective agonists to Singapore this morning as the ...